Showing results (221-230 of 271) with videos related to

Sort By:
Pageof 28
Journal of Pharmaceutical Sciences|April 27, 2013
Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometryPrakash Manikwar, Ranajoy Majumdar, John M Hickey, et al.
Cardiovascular and Interventional Radiology|September 27, 2024
Comparison of Chemotherapy Combined with Percutaneous Electroporation and Chemotherapy Alone in the Management of Locally Advanced Gallbladder Carcinoma (GBC): A Study ProtocolN Kalra, H Bhujade, A Baloji, et al.
Hepatobiliary & Pancreatic Diseases International : HBPD INT|August 5, 2011
One hundred and seventy-eight consecutive pancreatoduodenectomies without mortality: role of the multidisciplinary approachJaswinder S Samra, Raul Alvarado Bachmann, Julian Choi, et al.
European Journal of Clinical Investigation|November 2, 2024
Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patientsJosef E Gillson, Sooin Byeon, Angela Chou, et al.
The Journal of Biological Chemistry|May 23, 2006
Ectoadenylate kinase and plasma membrane ATP synthase activities of human vascular endothelial cellsEllen E Quillen, Gale C Haslam, Hardeep S Samra, et al.
Pathology|March 26, 2009
Synoptic reporting improves histopathological assessment of pancreatic resection specimensAnthony J Gill, Amber L Johns, Robert Eckstein, et al.
International Journal of Cancer|October 31, 2020
A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinomaSumit Sahni, Advait R Pandya, William J Hadden, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 24, 2018
Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort studyChristopher B Nahm, John Turchini, Nigel Jamieson, et al.
Human Pathology|August 7, 2018
ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumorsAngela Chou, Malinda Itchins, Philip R de Reuver, et al.
Cancers|July 27, 2022
The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resectable Pancreatic CancerChristopher B Nahm, John Turchini, Sumit Sahni, et al.
Pageof 28